Status:
RECRUITING
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
Lead Sponsor:
First People's Hospital of Hangzhou
Collaborating Sponsors:
Zhejiang University
General Hospital of Ningxia Medical University
Conditions:
Signet Ring Cell Carcinoma of the Lung
Eligibility:
All Genders
18-85 years
Brief Summary
This study aims to reveal the molecular characteristics and immune microenvironmental profile of signet ring cell carcinoma of the lung (LSRCC) in the Chinese population through integrated multi-omics...
Detailed Description
This study aims to reveal the molecular characteristics and immune microenvironmental profile of signet ring cell carcinoma of the lung (LSRCC) in the Chinese population through integrated multi-omics...
Eligibility Criteria
Inclusion
- Histologically confirmed, previously untreated LSRCC; 2. Adequate FFPE tumor tissue and paired adjacent non-tumor tissue available; 3. Expected survival ≥ 12 weeks; 4. Patients (or their legal guardians) willing and able to provide written informed consent; 5.Availability of complete pathology and imaging data.
Exclusion
- 1\. Prior systemic anticancer therapy; 2. Secondary LSRCC (i.e., metastatic signet ring cell carcinoma originating from a non-lung primary site); 3. Concurrent other malignancies; 4. Incomplete pathology results, missing imaging data, or unreliable follow-up information; 5. Pregnancy or lactation
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT07207278
Start Date
September 1 2025
End Date
August 31 2027
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine
Hangzhou, Zhejiang, China, 310006